This is a translation of a press release in Swedish published December 29, 2020 Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the company's new capsule product with KAND567 has been evaluated in a successful phase I study in...
This is a translation of a press release in Swedish published December 21, 2020 Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the company has established a Scientific Advisory Board consisting of three leading scientists in the fields of...
Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for the development of Kancera's series of HDAC6 inhibitors...
Recent Comments